The American Journal of Managed Care11d
Community, Connection, and Sharing the Science at CROI 2025
Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...
Aidsmap25d
aidsmap returns with reporting from the Conference on Retroviruses and Opportunistic Infections (CROI)
News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...
El Mundo on MSN17d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two injections per year to one against HIV. "It is a hopeful step and the study data are ...
The Business Journals19d
Big S.F. science conference offers innovation, research — but key attendees missing
As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...
The American Journal of Managed Care22d
CROI to Present New Insights on Long COVID Risk, HIV Cure
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential causes, biomarkers, and the significance of viral rebound. A virologist ...
BioWorld15d
Long COVID science is progressing, though therapies have not yet followed
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...
AllAfrica on MSN8d
A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing ...
Tecovirimat is safe but ineffective as treatment for clade II mpox
Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. "This study brought us a step forward in better understanding mpox disease ...
Healio12d
Investigational combo noninferior to current HIV therapy
Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...
Bay Area Reporter16d
At CROI conference, HIV activists sound alarm on Trump policies
AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United States and worldwide.
Healio15d
Long-acting treatment benefits postpartum women with HIV and their babies
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant ...